Anixa Biosciences, Inc.

Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
    • COVID-19
      • Introduction
      • Science
      • Collaborators
  • Pipeline
  • Investors
    • Overview
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
  • Contact Us

News Releases

Investors

Investors

  • Overview
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
    • RSS News Feed
  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015

Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic

May 26, 2021

Anixa Biosciences and Moffitt Cancer Center Receive Additional Information Request from US FDA for CAR-T IND Application

May 20, 2021

OntoChem Assigns Anixa Covid-19 Drug Discovery Project to MolGenie

May 7, 2021

Anixa Biosciences and Moffitt Cancer Center Report US FDA Request of Additional Information for CAR-T Therapy

April 19, 2021

Anixa Biosciences and OntoChem Enter Next Stage of Development for Covid-19 Therapeutic

April 5, 2021

Anixa Biosciences Increases Previously Announced Bought Deal Offering of Common Stock to $22.5 Million

March 22, 2021

Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock

March 22, 2021

Anixa Biosciences and Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy

March 22, 2021

Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology

March 12, 2021

Anixa Biosciences to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

March 8, 2021

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...20
  • Next »

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Jun 21, 2022

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology

Read More...
May 5, 2022

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

Read More...
Apr 28, 2022

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Read More...
Copyrights © 2022 Anixa Biosciences, Inc.. All Rights Reserved.
Privacy Policy Disclaimer Sitemap